|
| Effect of Sijunzi Decoction on monoamine neurotransmitter in different brain regions of rats with spleen deficiency |
| Hits 1347 Download times 1634 Received:October 11, 2008 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2009.02.24 |
| Key Words
spleen deficiency syndrome;5-HT;DA;Sijunzi decoction |
| Author Name | Affiliation | | CHEN Wen-qiang | Xuan-wu Hospital, Capital Medical University, Beijing 100053, China | | HUANG Xiao-bo | Xuan-wu Hospital, Capital Medical University, Beijing 100053, China | | LI Zong-xin | Xuan-wu Hospital, Capital Medical University, Beijing 100053, China | | 王宁群 | Xuan-wu Hospital, Capital Medical University, Beijing 100053, China | | 周茗 | Xuan-wu Hospital, Capital Medical University, Beijing 100053, China | | 吴燕川 | Xuan-wu Hospital, Capital Medical University, Beijing 100053, China | | 郭德玉 | Xuan-wu Hospital, Capital Medical University, Beijing 100053, China | | 陈玉静 | Xuan-wu Hospital, Capital Medical University, Beijing 100053, China |
|
| Abstract
|
| [Objective] To analyze the change of monoamine neurotransmitter content in different brain regions in rats with spleen deficiency treated with Sijunzi decoction and explore the treatment mechanism. [Methods] Sixty rats were randomly divided into three groups:control group,model group and treatment group. The 5-HT and DA content in hippocamp,hypothalamus and corpus striatum were measured with high performance liquid chromatograph. [Results] Compared with control group,the content of 5-HT in rats with spleen deficiency was significantly ascended,and the content of DA significantly descended (P<0.05). After treatment with Sijunzi decoction,5-HT and DA came back to normal. Compared with spleen deficiency rats,the content of DA was significantly ascended in rats of treatment group(P<0.05). [Conclusion] There is a consanguineous relationship between spleen deficiency syndrome and rats’ monoamine neuro-transmitter. Spleen deficiency syndrome appears the central mechanism. Sijunzi decoction can be used to treat the patients with spleen deficiency syndrome by regulating monoamine neurotransmitter. |
|
|
|
|
|
|
|
